PasitheaLogo.png
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
September 09, 2024 08:01 ET | Pasithea
Pasithea completes chronic toxicity studies for PAS-004, showing safety and potential for long-term use in NF1 and cancer treatment; Phase 1 trial ongoing
PasitheaLogo.png
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
September 03, 2024 08:02 ET | Pasithea
Pasithea Tx appoints Dr. Rebecca Brown, an expert in Neurofibromatosis and Director at Mount Sinai, to its Scientific Advisory Board to aid in PAS-004.
PasitheaLogo.png
Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 28, 2024 09:11 ET | Pasithea
Pasithea Therapeutics will present at H.C. Wainwright’s Global Investment Conference, highlighting PAS-004 development for NF1 and cancer.
PasitheaLogo.png
Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
May 28, 2024 06:59 ET | Pasithea
Pasithea to present preclinical data at ASCO 2024 showing PAS-004 superior inhibition of NRAS cancer cells and xenograft tumors compared to current MEKi's
PasitheaLogo.png
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
April 24, 2024 07:59 ET | Pasithea
Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.
PasitheaLogo.png
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
February 13, 2024 07:59 ET | Pasithea
Pasithea Tx activates four U.S. sites for Phase 1 Trial of its next-gen MEK inhibitor, aiming to assess safety, efficacy, and biomarker data.
PasitheaLogo.png
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
January 02, 2024 08:35 ET | Pasithea
Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3.
PasitheaLogo.png
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
December 28, 2023 17:00 ET | Pasithea
Pasithea Therapeutics (Nasdaq: KTTA) adjourns stockholder meeting again to Dec 29 for voting on charter amendments, after partial adjournment on Dec 19.
PasitheaLogo.png
Pasithea Therapeutics Announces Results from 2023 Annual Meeting
December 19, 2023 17:19 ET | Pasithea
Disclosure related to the annual meeting of Pasithea Therapeutics (Nasdaq: KTTA)
PasitheaLogo.png
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
November 29, 2023 16:27 ET | Pasithea
Pasithea Therapeutics adjourns 2023 annual meeting of stockholders.